10,000 Patient Study in North America
100,000+ Tests Performed in the U.S.
Finds Right & Left Sided Cancers
Detects Colorectal Cancer & Precancerous Lesions (Stage 1 & 2)

ColonSentry® is a proprietary liquid biopsy test that uses advanced gene expression (mRNA) technology for the early identification of Colorectal Cancer (CRC). ColonSentry®, was the first liquid biopsy for CRC, using our patented Sentinel Principle Technology Platform.

Following a ColonSentry® test result, if the score is elevated in a patient at average risk, there is an increased probability the patient may have a pre-cancerous lesion or colorectal cancer. Studies have shown 80-95% of patients who refuse Colonoscopy will comply with a blood test. Patients are then 2 times more likely to comply with Colonoscopy. ColonSentry®, in advance of Colonoscopy finds 2.1 to 4.7 times more CRC lesions. ColonSentry can reduce healthcare costs by more than 20% through early interventions.